Loading people...
Freda Lewis-Hall is a distinguished Venture Partner at Catalio Capital and a globally recognized leader in medicine and pharmaceuticals. She previously served as Executive Vice President and Chief Medical Officer at Pfizer, bringing extensive expertise in drug development, patient advocacy, and public health to her current role.
As a Venture Partner at Catalio Capital, Freda Lewis-Hall focuses on breakthrough biomedical technologies. Her investment interests include novel therapeutics, advanced diagnostics, and disruptive digital health solutions that address significant unmet medical needs and have the potential to transform patient care.
Freda Lewis-Hall works as a Venture Partner at Catalio Capital, a leading investment firm dedicated to supporting innovative biomedical companies. She leverages her vast experience to guide the firm's investment strategies and portfolio development.
Dr. Freda Lewis-Hall is a corporate board director and life sciences executive based in the United States. She earned her medical degree from the Howard University College of Medicine and has spent over four decades working in frontline clinical medicine and biopharmaceutical research. Before retiring in early 2020, she served as the Executive Vice President, Chief Medical Officer, and Chief Patient Officer at Pfizer, following senior medical leadership positions at Bristol-Myers Squibb and AstraZeneca. She currently holds corporate governance roles across the healthcare sector, serving on the boards of directors for Sanofi, Exact Sciences, Emira Pharmaceuticals, and SpringWorks Therapeutics. Additionally, she previously served as the Vice Chair of the Patient-Centered Outcomes Research Institute. Her executive career and ongoing advisory work focus on biopharmaceutical innovation, clinical research strategy, and advancing health equity within patient-centric medical affairs.
Freda Lewis-Hall serves as a highly respected Venture Partner at Catalio Capital, a leading firm dedicated to investing in breakthrough biomedical technologies. In this pivotal role, Dr. Lewis-Hall brings an unparalleled depth of experience and strategic vision to the firm's investment strategies and portfolio development. Her contributions are instrumental in identifying and evaluating innovative companies poised to revolutionize healthcare.
Dr. Lewis-Hall's investment focus at Catalio Capital aligns with the firm's mission to support cutting-edge science and medical advancements. She is particularly interested in novel therapeutics, advanced diagnostics, and disruptive digital health solutions that address significant unmet medical needs. Her expertise helps guide Catalio's investments towards opportunities with the highest potential for clinical impact and market success, ensuring that capital is deployed to foster meaningful progress in patient care.
Prior to joining Catalio Capital, Freda Lewis-Hall built an illustrious career as a global leader in medicine and pharmaceuticals. Most notably, she served as Executive Vice President and Chief Medical Officer at Pfizer, one of the world's largest pharmaceutical companies. During her tenure at Pfizer, she was responsible for the safe and appropriate use of Pfizer medicines globally, overseeing medical affairs, drug safety, and regulatory compliance. Her leadership was critical in shaping clinical development programs and ensuring patient access to innovative treatments.
Before her impactful role at Pfizer, Dr. Lewis-Hall held senior leadership positions at several other major pharmaceutical companies, including Vertex Pharmaceuticals, Bristol Myers Squibb, and Lilly. A board-certified psychiatrist, her early career included academic appointments and clinical practice, providing her with a foundational understanding of patient needs and the complexities of healthcare delivery. This diverse background equips her with a unique perspective on the entire drug development lifecycle, from early-stage research to commercialization and patient engagement.
While specific deal-by-deal investments as a Venture Partner are often strategic guidance rather than direct lead roles, Dr. Lewis-Hall's influence is evident in Catalio's commitment to pioneering biomedical ventures. Her extensive network and deep industry knowledge are invaluable assets, helping portfolio companies navigate regulatory landscapes, accelerate clinical trials, and build robust commercial strategies. Her board memberships on prominent healthcare companies like Bristol Myers Squibb, GRAIL, and Guardant Health further underscore her ongoing engagement and influence across the healthcare investment ecosystem, reflecting her dedication to advancing medical science and improving global health outcomes.
